Your browser doesn't support javascript.
loading
IL-6-GP130 signaling protects human hepatocytes against lipid droplet accumulation in humanized liver models.
Carbonaro, Marisa; Wang, Kehui; Huang, Hui; Frleta, Davor; Patel, Aditi; Pennington, Alexander; Desclaux, Mathieu; Moller-Tank, Sven; Grindley, Justin; Altarejos, Judith; Zhong, Jun; Polites, Greg; Poueymirou, William; Jaspers, Stephen; Kyratsous, Christos; Zambrowicz, Brian; Murphy, Andrew; Lin, John C; Macdonald, Lynn E; Daly, Christopher; Sleeman, Mark; Thurston, Gavin; Li, Zhe.
Afiliação
  • Carbonaro M; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.
  • Wang K; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.
  • Huang H; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.
  • Frleta D; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.
  • Patel A; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.
  • Pennington A; Pyxant Labs Inc., Salt Lake City, UT, USA.
  • Desclaux M; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.
  • Moller-Tank S; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.
  • Grindley J; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.
  • Altarejos J; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.
  • Zhong J; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.
  • Polites G; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.
  • Poueymirou W; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.
  • Jaspers S; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.
  • Kyratsous C; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.
  • Zambrowicz B; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.
  • Murphy A; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.
  • Lin JC; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.
  • Macdonald LE; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.
  • Daly C; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.
  • Sleeman M; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.
  • Thurston G; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.
  • Li Z; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.
Sci Adv ; 9(15): eadf4490, 2023 04 14.
Article em En | MEDLINE | ID: mdl-37058568
ABSTRACT
Liver steatosis is an increasing health issue with few therapeutic options, partly because of a paucity of experimental models. In humanized liver rodent models, abnormal lipid accumulation in transplanted human hepatocytes occurs spontaneously. Here, we demonstrate that this abnormality is associated with compromised interleukin-6 (IL-6)-glycoprotein 130 (GP130) signaling in human hepatocytes because of incompatibility between host rodent IL-6 and human IL-6 receptor (IL-6R) on donor hepatocytes. Restoration of hepatic IL-6-GP130 signaling, through ectopic expression of rodent IL-6R, constitutive activation of GP130 in human hepatocytes, or humanization of an Il6 allele in recipient mice, substantially reduced hepatosteatosis. Notably, providing human Kupffer cells via hematopoietic stem cell engraftment in humanized liver mice also corrected the abnormality. Our observations suggest an important role of IL-6-GP130 pathway in regulating lipid accumulation in hepatocytes and not only provide a method to improve humanized liver models but also suggest therapeutic potential for manipulating GP130 signaling in human liver steatosis.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Interleucina-6 / Fígado Gorduroso Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Interleucina-6 / Fígado Gorduroso Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article